ERBB2 and hepatocellular carcinoma: To examine the effect of H2-18 on ErbB2 signaling pathway, the trastuzumab-sensitive cell line BT-474 and the trastuzumab-resistant cell line HCC-1954 were treated with 5μg/ml anti-ErbB2 antibodies for 4h, and then cell lysates were subjected to western blot.